European listed biotech landscape: 2020 review and outlook for 2021

Table of Content 1. Intro on COVID-19 2. How the European listed biotech companies try to help for vaccines and therapies against COVID-19 3. 2020 Highlights (financing, Genmab, Morphosys, approvals, “Billion Euro Biotech Club”, valuations) 4. 2020 Lowlights (Galapagos, Genfit, DBV, IPOs, AIM) 5. 2020 Deals and M&As 6. 2020 Stock and Index Performances 7.[…]

Summary of the COVID-19 vaccine supply agreements for Europe (incl. the UK & Switzerland), the US, Japan, Canada, Australia (28/02/2021 update)

Change log: * The updates from 08/11/2020 and later include additional data in the tables since the first publication on 25/08/2020, and only in the tables. * Calculation errors were corrected on 20/11/2020 and on 12/12/2020 (errors in aggregate nb of doses and avg nb of course/inh. for the US data). * Major update for[…]